Company intelligence / Profile preview

Wellstat Immunotherapeutic

Gaithersburg/Rockville, Maryland, United Stateswellstar.org ↗

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Wellstat Therapeutics Corporation develops novel small molecule drugs targeting oncology and rare metabolic disorders. Its most notable achievements include FDA approvals for uridine triacetate-based products Vistogard® (for chemotherapy overdose) and Xuriden® (for hereditary orotic aciduria). Other pipeline assets target mitochondrial myopathies and solid tumors. Some programs have been discontinued.

Therapeutic areas: OncologyMetabolic DisordersRare DiseasesHematologyDermatologyNeurology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Wellstat Immunotherapeutic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellstat Immunotherapeutic.

Explore the full profile